Connect with us

Life Sciences

Researchers reveal key mechanism of NK cell dysfunction

A team led by Prof. WEI Haiming, Prof. ZHENG Xiaohu and Prof. TIAN Zhigang from the University of Science and Technology (USTC), collaborating with Prof….

Published

on

This article was originally published by BioEngineering

A team led by Prof. WEI Haiming, Prof. ZHENG Xiaohu and Prof. TIAN Zhigang from the University of Science and Technology (USTC), collaborating with Prof. HUANG Guangming’s team from USTC and Director YE Ben’s team from the First Affiliated Hospital of Anhui Medical University revealed the key mechanism of the loss of membrane protrusions on intratumoral natural killer (NK) cells, which impairs their ability to recognize and kill tumor cells, providing a new strategy for NK cell-based immunotherapy. This work was published in Nature Immunology on March 23th.

Tumors evade immune cytotoxicity by altering the surface topology of NK cells

Credit: Image by ZHENG Xiaohu et al.

A team led by Prof. WEI Haiming, Prof. ZHENG Xiaohu and Prof. TIAN Zhigang from the University of Science and Technology (USTC), collaborating with Prof. HUANG Guangming’s team from USTC and Director YE Ben’s team from the First Affiliated Hospital of Anhui Medical University revealed the key mechanism of the loss of membrane protrusions on intratumoral natural killer (NK) cells, which impairs their ability to recognize and kill tumor cells, providing a new strategy for NK cell-based immunotherapy. This work was published in Nature Immunology on March 23th.

NK cells play a crucial role in immunotherapy. However, NK cells’ ability to kill tumor cells is severely compromised in the tumor microenvironment and most advanced-stage tumors can evade the immune attack of NK cells. In order to restore the function of the intratumoral NK cells, it is important to understand the mechanism of their impairments.

The team used both transmission electron microscopy (TEM) and scanning electron microscopy (SEM) to clearly observe the distinct difference in surface topology of NK cells’ membranes in normal and tumor microenvironment. The membrane surfaces of normal NK cells have abundant protrusions, while the membrane surfaces of intratumoral NK cells are abnormally smooth, displaying very few protrusions.

Further research revealed that normal NK cells use membrane protrusions to recognize and form immunological synapses with tumor cells, through which the NK cells release granzyme to lyse tumor cells. With the loss of membrane protrusions, intratumoral NK cells from patients with advanced-stage cancer are unable to recognize and form contact with tumor cells, thereby lose the ability to kill tumor cells.

The team also developed a single-immunocyte mass spectrometry (MS) technology, which can detect the changes in the chemical components of intratumoral NK cell membranes, mainly the decrease in sphingomyelin (SM), confirming that the dysregulated serine metabolism in tumors is the main cause of the decrease in SM. Sphingomyelinase inhibitor can significantly increase the SM in intratumoral NK cell membranes, which can restore protrusion formation and improve NK cells’ ability to recognize and kill tumor cells. Results show that targeting sphingomyelinase demonstrates powerful synergistic antitumor efficacy when combined with immune checkpoint-targeted therapy.

This study revealed the key mechanism of NK cells dysfunction and immune evasion from the perspective of membrane topology, providing a new strategy for NK cell-based tumor immunotherapy.



Life Sciences

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending